RB1CC1 and neoplasm: However, treating cells with JNK agonists Clolar and OXA neither stimulated nuclear translocation of RB1CC1 nor influenced ferroptosis sensitivity in H460 cells (Figure S6H,I), suggesting that JNK agonists might only reinforce ferroptosis‐based therapy in ferroptosis‐inducible tumour cells.